174 related articles for article (PubMed ID: 33230623)
1. 4Ei-10 interdiction of oncogenic cap-mediated translation as therapy for non-small cell lung cancer.
Jacobson BA; Ahmad Z; Chen S; Waldusky G; Dillenburg M; Stoian E; Cambron DA; Patel AJ; Patel MR; Wagner CR; Kratzke RA
Invest New Drugs; 2021 Jun; 39(3):636-643. PubMed ID: 33230623
[TBL] [Abstract][Full Text] [Related]
2. Treatment of breast and lung cancer cells with a N-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) results in chemosensitization to gemcitabine and induced eIF4E proteasomal degradation.
Li S; Jia Y; Jacobson B; McCauley J; Kratzke R; Bitterman PB; Wagner CR
Mol Pharm; 2013 Feb; 10(2):523-31. PubMed ID: 23289910
[TBL] [Abstract][Full Text] [Related]
3. Repression of oncogenic cap-mediated translation by 4Ei-10 diminishes proliferation, enhances chemosensitivity and alters expression of malignancy-related proteins in mesothelioma.
Ahmad Z; Jacobson BA; McDonald MW; Vattendahl Vidal N; Vattendahl Vidal G; Chen S; Dillenburg M; Okon AM; Patel MR; Wagner CR; Kratzke RA
Cancer Chemother Pharmacol; 2020 Feb; 85(2):425-432. PubMed ID: 31974652
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells.
Chen EZ; Jacobson BA; Patel MR; Okon AM; Li S; Xiong K; Vaidya AJ; Bitterman PB; Wagner CR; Kratzke RA
Invest New Drugs; 2014 Aug; 32(4):598-603. PubMed ID: 24711125
[TBL] [Abstract][Full Text] [Related]
5. Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide.
Jacobson BA; Thumma SC; Jay-Dixon J; Patel MR; Dubear Kroening K; Kratzke MG; Etchison RG; Konicek BW; Graff JR; Kratzke RA
PLoS One; 2013; 8(11):e81669. PubMed ID: 24260583
[TBL] [Abstract][Full Text] [Related]
6. Antisense oligonucleotide targeting eukaryotic translation initiation factor 4E reduces growth and enhances chemosensitivity of non-small-cell lung cancer cells.
Thumma SC; Jacobson BA; Patel MR; Konicek BW; Franklin MJ; Jay-Dixon J; Sadiq A; De A; Graff JR; Kratzke RA
Cancer Gene Ther; 2015 Aug; 22(8):396-401. PubMed ID: 26227824
[TBL] [Abstract][Full Text] [Related]
7. The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation.
Fan S; Li Y; Yue P; Khuri FR; Sun SY
Neoplasia; 2010 Apr; 12(4):346-56. PubMed ID: 20360945
[TBL] [Abstract][Full Text] [Related]
8. 4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma.
De A; Jacobson BA; Peterson MS; Jay-Dixon J; Kratzke MG; Sadiq AA; Patel MR; Kratzke RA
Invest New Drugs; 2018 Apr; 36(2):217-229. PubMed ID: 29116477
[TBL] [Abstract][Full Text] [Related]
9. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
10. Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.
Rundall BK; Denlinger CE; Jones DR
Surgery; 2005 Aug; 138(2):360-7. PubMed ID: 16153448
[TBL] [Abstract][Full Text] [Related]
11. Measles vaccine strains for virotherapy of non-small-cell lung carcinoma.
Patel MR; Jacobson BA; Belgum H; Raza A; Sadiq A; Drees J; Wang H; Jay-Dixon J; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
J Thorac Oncol; 2014 Aug; 9(8):1101-10. PubMed ID: 25157763
[TBL] [Abstract][Full Text] [Related]
12. Cap-dependent translation blockade and fixed dose-rate gemcitabine: interaction in an in vitro bioreactor system.
Williams BW; Chang JJ; Chi RM; Marker PH; Frethem CD; Le CT; Kratzke RA; Kirstein MN
Cancer Lett; 2009 Oct; 284(1):37-46. PubMed ID: 19442436
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Denlinger CE; Rundall BK; Keller MD; Jones DR
Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
Ceresa C; Giovannetti E; Voortman J; Laan AC; Honeywell R; Giaccone G; Peters GJ
Mol Cancer Ther; 2009 May; 8(5):1026-36. PubMed ID: 19383850
[TBL] [Abstract][Full Text] [Related]
15. Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo.
Jacobson BA; Alter MD; Kratzke MG; Frizelle SP; Zhang Y; Peterson MS; Avdulov S; Mohorn RP; Whitson BA; Bitterman PB; Polunovsky VA; Kratzke RA
Cancer Res; 2006 Apr; 66(8):4256-62. PubMed ID: 16618749
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis by gemcitabine in non-small cell lung cancer cell line KNS62 is induced downstream of caspase 8 and is profoundly blocked by Bcl-xL over-expression.
Kurdow R; Schniewind B; Zoefelt S; Boenicke L; Boehle AS; Dohrmann P; Kalthoff H
Langenbecks Arch Surg; 2005 Jun; 390(3):243-8. PubMed ID: 15726400
[TBL] [Abstract][Full Text] [Related]
17. EGPI-1, a novel eIF4E/eIF4G interaction inhibitor, inhibits lung cancer cell growth and angiogenesis through Ras/MNK/ERK/eIF4E signaling pathway.
Qi X; Zhang S; Chen Z; Wang L; Zhu W; Yin C; Fan J; Wu X; Wang J; Guo C
Chem Biol Interact; 2022 Jan; 352():109773. PubMed ID: 34902296
[TBL] [Abstract][Full Text] [Related]
18. Design of nucleotide-mimetic and non-nucleotide inhibitors of the translation initiation factor eIF4E: Synthesis, structural and functional characterisation.
Soukarieh F; Nowicki MW; Bastide A; Pöyry T; Jones C; Dudek K; Patwardhan G; Meullenet F; Oldham NJ; Walkinshaw MD; Willis AE; Fischer PM
Eur J Med Chem; 2016 Nov; 124():200-217. PubMed ID: 27592390
[TBL] [Abstract][Full Text] [Related]
19. Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer.
Li Y; Fan S; Koo J; Yue P; Chen ZG; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
Cancer Biol Ther; 2012 Mar; 13(5):272-80. PubMed ID: 22236867
[TBL] [Abstract][Full Text] [Related]
20. Combination of DN604 with gemcitabine led to cell apoptosis and cell motility inhibition via p38 MAPK signaling pathway in NSCLC.
Wang X; Chen F; Gou S
Bioorg Chem; 2020 Nov; 104():104234. PubMed ID: 32920359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
